Detection of mRNA for the terminal complement components C5, C6, C8 and C9 in human umbilical vein endothelial cells in vitro

被引:14
|
作者
Langeggen, H
Berge, KE
Macor, P
Fischetti, F
Tedesco, F
Hetland, G
Berg, K
Johnson, E
机构
[1] Univ Oslo, Ulleval Hosp, Dept Surg Gastroenterol, N-0407 Oslo, Norway
[2] Univ Oslo, Ulleval Hosp, Dept Med Genet, N-0407 Oslo, Norway
[3] Univ Trieste, Dept Physiol & Pathol, I-34127 Trieste, Italy
[4] Natl Inst Publ Hlth, Dept Environm Med, N-0462 Oslo, Norway
[5] Univ Oslo, Inst Med Genet, Oslo, Norway
关键词
mRNA; TCC; HUVEC;
D O I
10.1111/j.1600-0463.2001.tb00016.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Human umbilical vein endothelial cells (HUVEC) have previously been shown to synthesize the functional terminal pathway of complement based on the detection by radioimmunoassay of the terminal complement complex (TCC) on coincubated agarose beads. In addition, C7 secretion by these cells in amounts comparable to C3, as well as C7 mRNA, has recently been demonstrated. However, it has not been possible to detect C5-6 and C8 in the fluid phase, and only trace amounts of soluble C9. Against this background we examined whether mRNA for the remaining terminal complement factors was present in HUVEC. By the use of reverse transcription (RT)-polymerase chain reaction (PCR) and Northern blot the presence of mRNA for complement factors C5, C6, C8 and C9 was demonstrated.
引用
收藏
页码:73 / 78
页数:6
相关论文
共 15 条
  • [1] Effects of C5a and FMLP on Interleukin-8 Production and Proliferation of Human Umbilical Vein Endothelial Cells
    H. Langeggen
    E. Johnson
    G. Hetland
    Inflammation, 2001, 25 : 83 - 89
  • [2] Effects of C5a and FMLP on interleukin-8 production and proliferation of human umbilical vein endothelial cells
    Langeggen, H
    Johnson, E
    Hetland, G
    INFLAMMATION, 2001, 25 (02) : 83 - 89
  • [3] HLA-C expression level in both unstimulated and stimulated human umbilical vein endothelial cells is defined by allotype
    Carey, B. Sean
    Poulton, Kay, V
    Poles, Anthony
    HLA, 2020, 95 (06) : 532 - 542
  • [4] c-Jun N-terminal kinases inhibitor suppresses the TNF-α induced MCP-1 expression in human umbilical vein endothelial cells
    Rania Abdel Muneem Ahmed
    Koji Murao
    Hitomi Imachi
    Kazuya Yoshida
    Hiroaki Dobashi
    Naohisa Hosomi
    Toshihiko Ishida
    Endocrine, 2009, 35 : 184 - 188
  • [5] c-Jun N-terminal kinases inhibitor suppresses the TNF-α induced MCP-1 expression in human umbilical vein endothelial cells
    Ahmed, Rania Abdel Muneem
    Murao, Koji
    Imachi, Hitomi
    Yoshida, Kazuya
    Dobashi, Hiroaki
    Hosomi, Naohisa
    Ishida, Toshihiko
    ENDOCRINE, 2009, 35 (02) : 184 - 188
  • [6] NOVEL SYNTHESIS OF CARBOCYCLIC OXETANOCIN ANALOGS (2-ALKOXY-C.OXT-A) AND THEIR TUBE FORMATION ACTIVITIES OF HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS (HUVEC)
    Sakakibara, Norikazu
    Tsukamoto, Ikuko
    Tsuruta, Takashi
    Takata, Maki
    Konishi, Ryoji
    Maruyama, Tokumi
    HETEROCYCLES, 2012, 85 (05) : 1105 - 1116
  • [7] Interluekin-1 alpha, interleukin 6 and tumor necrosis factor alpha increase the synthesis and expression of the functional alternative and terminal complement pathways by human umbilical vein endothelial cells in vitro
    Berge, V
    Johnson, E
    Berge, KE
    APMIS, 1996, 104 (03) : 213 - 219
  • [8] miR-181c-3p and-5p promotes high-glucose-induced dysfunction in human umbilical vein endothelial cells by regulating leukemia inhibitory factor
    Shen, Xinghua
    Li, Yunling
    Sun, Guizhi
    Guo, Dianlong
    Bai, Xiuping
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2018, 115 : 509 - 517
  • [9] BRADYKININ-POTENTIATING PEPTIDE-10C INCREASES L-ARGININE AND NITRIC OXIDE PRODUCTION IN HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS FROM PREECLAMPTIC PREGNANCIES
    Benedetti, G.
    Hoshida, M. S.
    Morais, K. L.
    Lameu, C.
    Oliveira, L. G.
    Serrano, S. M. T.
    PLACENTA, 2010, 31 (09) : A81 - A81
  • [10] Enhanced angiogenesis of human umbilical vein endothelial cells via THP-1-derived M2c-like macrophages and treatment with proteasome inhibitors 'bortezomib and ixazomib'
    Engur-Ozturk, Selin
    Kaya-TIlkI, Elif
    Canturk, Zerrin
    Dikmen, Miris
    APMIS, 2024, 132 (08) : 594 - 607